Evidence map›Paper›PMID 34471236›Full record

ArticleOncogene2021

SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis.

Ping Tan, Manli Wang, Ailing Zhong, Yiyun Wang, Jiajia Du, Jian Wang, Lu Qi, Zhanying Bi, Peng Zhang, Tianhai Lin and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. The role of acetylation and deacetylation in cancer metabolism.Clinical and translational medicine · 2025
    Review
  11. eLife · 2024
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. The role of organoids in cancer research.Experimental hematology & oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Ping Tan *Department of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0002-7445-3577
Manli Wang *Department of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Ailing ZhongDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Yiyun WangDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Jiajia DuDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Jian WangDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Lu QiDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Zhanying BiDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Peng ZhangDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Tianhai LinDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Jiapeng ZhangDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Lu YangDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Jingyao ChenDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Ping HanDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Qiyong GongDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0002-5912-4871
Yu LiuDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Chong ChenDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. chongchen@scu.edu.cn.ORCID http://orcid.org/0000-0002-6787-0495
Qiang WeiDepartment of Urology, Institute of Urology, Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. weiqiang@scu.edu.cn.ORCID http://orcid.org/0000-0003-3750-3042
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are unmet clinical needs for novel therapeutic targets and drugs for bladder cancer. Majority of previous work relied on limited bladder cancer cell lines, which could not well represent the tumor heterogeneity and pathology of this disease. Recently, it has been shown that cancer organoids can recapitulate pathological and molecular properties of bladder cancer. Here, we report, by our knowledge, the first bladder cancer organoid-based small molecule screening for epigenetic drugs. We found that SRT1720, a Sirtuin 1 (SIRT1) activator, significantly inhibits the growth of both mouse and human bladder cancer organoids. And it also restrains the development of mouse in situ bladder cancer and human PDX bladder cancer. Mutation of Sirt1 promotes the growth of cancer organoids and decreases their sensitivity to SRT1720, which validate Sirt1 as the target of SRT1720 in bladder cancer. Mechanistically, SRT1720 treatment represses the hypoxia pathway through deacetylating HIF1α by activating Sirt1. Genetic or pharmaceutic inhibitions of HIF mimic the anti-tumor effect of SRT1720. Furthermore, the SIRT1-repressed gene signature is associated with the hypoxia target gene signature and poor prognosis in human bladder cancers. Thus, our study demonstrates the power of cancer organoid-based drug discovery and, in principle, identifies SRT1720 as a new treatment for bladder cancer.

Indexed as

AcetylationAnimalsDrug Screening Assays, AntitumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHeterocyclic Compounds, 4 or More RingsHumansHypoxia-Inducible Factor 1, alpha SubunitMiceMutationOrganoidsSirtuin 1Tumor HypoxiaUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysHeterocyclic Compounds, 4 or More RingsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitSIRT1 protein, humanSirtuin 1SRT1720

Identifiers

PMID34471236
OpenAlexW3196759725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.